NCT05248685 2025-06-11
Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia
Beijing Boren Hospital
Phase 1 Withdrawn
Clinical Trials
78 trialsNCT03560908 2025-05-01
Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation
Institute of Hematology & Blood Diseases Hospital, China
Phase 1 Withdrawn
NCT05595135 2025-04-29
Mobile Intervention to Improve Adherence of Oral Anti-cancer Medications Among Acute Myeloid Leukemia Patients, the txt4AML Study
Thomas Jefferson University
Phase NA Withdrawn
NCT05766514 2025-04-22
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
University of Florida
Phase 2 Withdrawn
NCT06351306 2025-03-24
DEC-C and Thioguanine for R/R AML
Columbia University
Phase 2 Withdrawn
NCT06113289 2025-03-12
A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT06200441 2025-01-29
Correlation of Serum Gasdermin-D and NLRP-3 Inflammasome Levels With GVHD Biomarkers and Endothelial Damage Markers in Graft-Versus-Host Disease
Ankara University
Withdrawn
NCT05266950 2024-11-14
Safety and Efficacy Study of CI-135 CAR-T Cells in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
Beijing Boren Hospital
Phase 1 Withdrawn
NCT04982354 2024-10-01
Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia
Baptist Health South Florida
Phase 1/2 Withdrawn
NCT05784844 2024-09-19
Antimicrobial Revision in Persistent Febrile Neutropenia
Wake Forest University Health Sciences
Phase 4 Withdrawn
NCT05823480 2024-09-19
Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS
City of Hope Medical Center
Phase 1 Withdrawn
NCT05854966 2024-09-19
CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Wake Forest University Health Sciences
Phase 2 Withdrawn
NCT06586099 2024-09-19
Tislelizumab with Azacitidine in the Treatment of R/R AML
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Withdrawn
NCT06337331 2024-06-14
Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant
Northside Hospital, Inc.
Phase 2 Withdrawn
NCT05309018 2024-05-23
LAMIPA
Centre Hospitalier Régional Metz-Thionville
Withdrawn
NCT05895201 2024-04-29
High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD
Indiana University
Phase 1/2 Withdrawn
NCT05720988 2024-03-08
Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT05829434 2024-02-12
MAGROLIC
University of Leipzig
Phase 2 Withdrawn
NCT06180863 2023-12-26
Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients
Yale University
Phase 2 Withdrawn
NCT05201183 2023-12-11
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Indiana University
Phase 1/2 Withdrawn
NCT04361058 2023-12-05
Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide
SCRI Development Innovations, LLC
Phase 1 Withdrawn
NCT05321940 2023-12-04
Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias
University of Miami
Phase 1 Withdrawn
NCT05519527 2023-08-31
STI-6129 CD38 ADC for the Treatment of Patients With Relapsed or Refractory Systemic ALL Amyloidosis
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00816413 2023-08-14
Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
University of Nebraska
Phase 1/2 Withdrawn
NCT05330377 2023-04-25
GM-CLAG in Relapsed/Refractory FLT3-mutated AML
University of Kentucky
Phase 1 Withdrawn
NCT04354025 2023-04-04
Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML
Washington University School of Medicine
Phase 2 Withdrawn
NCT02863458 2023-03-13
DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the US
The Cleveland Clinic
Withdrawn
NCT05513612 2023-03-01
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
Shanghai Pudong Hospital
Phase 1 Withdrawn
NCT04530695 2023-02-22
Diagnosis and Treatment of Periodontal Disease in Patients With AML
Masonic Cancer Center, University of Minnesota
Phase NA Withdrawn
NCT00003407 2023-02-02
Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML
Rush University Medical Center
Phase 2 Withdrawn
NCT04282174 2022-09-27
2019-KOE-001
Baptist Health South Florida
Phase 2 Withdrawn
NCT04655391 2022-06-09
Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation
City of Hope Medical Center
Phase 1 Withdrawn
NCT04676243 2022-05-25
Q-SOC
University Hospital Heidelberg
Phase 3 Withdrawn
NCT04893915 2022-03-11
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Washington University School of Medicine
Phase 2 Withdrawn
NCT04044209 2022-01-20
A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
Yale University
Phase 2 Withdrawn
NCT00003405 2021-10-14
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
Rush University Medical Center
Phase 2 Withdrawn
NCT04296214 2021-07-09
Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia
Grupo Cooperativo de Hemopatías Malignas
Withdrawn
NCT03066466 2021-04-27
Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT
Loyola University
Phase 3 Withdrawn
NCT01599429 2021-04-14
TEP-FLT-LMA
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Withdrawn
NCT03881735 2021-03-10
Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation
Roswell Park Cancer Institute
Phase 2 Withdrawn
NCT03515707 2021-02-01
Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Phase 2 Withdrawn
NCT04493099 2020-11-12
Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML
M.D. Anderson Cancer Center
Phase 1/2 Withdrawn
NCT04128020 2020-10-12
Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia
Big Ten Cancer Research Consortium
Phase 1 Withdrawn
NCT03121079 2020-09-23
Interferon-α Prevents Leukemia Relapse of AML Patients After Transplantation
Peking University People's Hospital
Phase NA Withdrawn
NCT00004114 2020-07-31
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT04013880 2020-07-07
ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
Vanderbilt-Ingram Cancer Center
Phase 1/2 Withdrawn
NCT00006451 2020-01-03
Bone Marrow Transplantation in Treating Patients With Leukemia
Masonic Cancer Center, University of Minnesota
Phase 3 Withdrawn
NCT03752138 2019-05-06
TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT03291353 2019-04-19
Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia
University of Pittsburgh
Phase EARLY_PHASE1 Withdrawn
NCT03705858 2019-03-08
Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia
Columbia University
Phase 1 Withdrawn